Proper authorization is vital for efficient healthcare delivery, ensuring patients receive timely and necessary treatments
Clinical Rationale for Early AOM Intervention Traditional obesity management often follows a fixed-duration behavioral therapy (BT) approach before considering medication, yet mounting evidence suggests this may not be optimal for many patients
GLP-1 is an incretin hormone naturally produced in the intestines that plays a crucial role in glucose metabolism and appetite regulation
With enhancement strategies, the math becomes more reasonable
Current clinical practice guidelines from organizations such as the American Association of Clinical Endocrinology (AACE), the Endocrine Society, and the American Diabetes Association (ADA) support long-term use of anti-obesity medications when clinically indicated
The risks of doing so including infection, incorrect dosing, and adverse reactions without medical support are substantial